Different receptor profiles
Retatrutide is studied as a GLP-1, GIP and glucagon receptor agonist. Tirzepatide is studied as a dual GIP and GLP-1 receptor agonist. The additional receptor target is a mechanistic distinction, not a stand-alone ranking of benefit.
The development code LY3437943 refers to Retatrutide; LY3298176 refers to Tirzepatide. A development code helps identify literature but does not verify the contents of a supplied vial.
Why separate trials do not produce a buying ranking
The cited Retatrutide phase 2 publication and Tirzepatide obesity trial used their own populations, interventions, comparators and follow-up periods. Comparing a headline percentage across those trials is not equivalent to a randomised head-to-head comparison.
Read eligibility, endpoints, missing-data handling, adverse events and follow-up together. A trial result concerns the tested formulation and protocol; it is not a certificate for a separately sold research material.
Research vials and finished medicines
Our catalogue presentations are laboratory materials. They are not prescription pens and are not substitutes for finished medicines. Shared compound names do not establish equivalent formulation, regulatory status, stability or quality controls.
For procurement, match exact identity, labelled amount, available analytical documentation and the intended laboratory application. Questions about a medicine or treatment belong with an appropriately qualified professional.
INR prices and availability
The linked product pages show current configured presentations and prices. Check the selected size and stock before sending an enquiry. A rupee-per-milligram comparison cannot express receptor activity, therapeutic equivalence or human safety.
Confirm the delivery PIN code and batch documents separately. Do not use this comparison to choose a personal dose, schedule or administration method.